Pacira BioSciences falls after co cuts jobs amid manufacturing upgrade

Shares of drugmaker Pacira BioSciences PCRX.O fall ~5% to $22.02 premarket

PCRX says in an SEC filing that it will cut 71 jobs, or about 8% of its workforce, at its San Diego Science Center after upgrading to larger manufacturing suites for its EXPAREL pain management product

EXPAREL is an FDA-approved drug used for postsurgical analgesia, which means it helps reduce or prevent pain after surgery, that allows patients to feel more comfortable as they recover

The company says it expects to take a pre-tax charge of $2.4–$2.8 million in Q3 2025 for severance and related costs

As of last close, PCRX stock up ~23% YTD